Home/Pipeline/BRII-179 (VBI-2601)

BRII-179 (VBI-2601)

Chronic Hepatitis B

Phase 2a/2bActiveNCT04485663

Key Facts

Indication

Chronic Hepatitis B

Phase

Phase 2a/2b

Status

Active

Company

Brii Biosciences

About Brii Biosciences

Founded in 2018, Brii Biosciences is a publicly traded biotech with a mission to address major public health challenges in infectious diseases and CNS disorders. Its core strategy involves in-licensing and co-developing clinical-stage assets, most notably achieving the first NMPA-approved COVID-19 neutralizing antibody combination in China. The company operates with a dual-US/China footprint, aiming to accelerate global innovation for patients in high-need markets.

View full company profile

Therapeutic Areas

Infectious Diseases Central Nervous System (CNS) Diseases

Other Chronic Hepatitis B Drugs

Drug	Company	Phase	Status
ZM-H1505R	Zhimeng Biopharma	Phase 1	Active
Undisclosed CAM	Zhimeng Biopharma	Clinical	Active
Undisclosed Immunomodulator	Zhimeng Biopharma	Clinical	Active
Selgantolimod (GS-9688)	Gilead	Phase 2	Active
Bepirovirsen	GSK	Phase III	Active
BRII-835 (VIR-2218) + BRII-179 (VBI-2601)	Brii Biosciences	Phase 2	Active
VIR-3434	Brii Biosciences	Preclinical/Phase 1 (ex-China)	Option Exercised
Collaboration with Aligos Therapeutics	Amoytop Biotech	Clinical	Collaboration announced July 2024
JNJ-3989	Johnson & Johnson	Phase 2	Active
APG-1387	Ascentage Pharma Group	Phase 2	Active
VTP-300	Barinthus Biotherapeutics	Phase 1b/2a	Active